{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:16:06Z","timestamp":1785284166700,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.yebeh.2018.04.020","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T07:25:00Z","timestamp":1527319500000},"page":"118-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-602X","authenticated-orcid":false,"given":"Maher","family":"Arabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Alsaadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Nasreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasem","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Dirani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.04.020_bb0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.12681","article-title":"Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study","volume":"55","author":"Wechsler","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: a multicentre open-label trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yebeh.2016.02.007","article-title":"Lacosamide tolerability in adult patients with partial-onset seizures: impact of planned reduction and mechanism of action of concomitant antiepileptic drugs","volume":"57","author":"Foldvary-Schaefer","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1684\/epd.2017.0907","article-title":"Adjunctive lacosamide for focal epilepsy: an open-label trial evaluating the impact of flexible titration and dosing on safety and seizure outcomes","volume":"19","author":"Baulac","year":"2017","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0045","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0050","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0060","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0065","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0070","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.0013-9580.2003.15003.x","article-title":"Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy","volume":"44","author":"Selwa","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.04.020_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018300507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018300507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T15:18:27Z","timestamp":1604330307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018300507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"alternative-id":["S1525505018300507"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.04.020","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}